Spero Therapeutics (NASDAQ:SPRO) Stock Price Breaks Below 200-Day Moving Average – Time to Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $2.00 and traded as low as $1.1705. Spero Therapeutics shares last traded at $1.19, with a volume of 906,915 shares trading hands.

Analyst Ratings Changes

SPRO has been the subject of several recent analyst reports. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a research note on Monday, September 14th. Zacks Research upgraded shares of Spero Therapeutics to a “hold” rating in a research report on Monday, September 14th. HC Wainwright boosted their target price on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Monday, September 14th. Finally, Weiss Ratings upgraded shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Price Performance

The business has a 50-day moving average of $1.20 and a 200 day moving average of $2.00. The company has a market capitalization of $69.31 million, a PE ratio of 10.82 and a beta of 1.50.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. As a group, research analysts anticipate that Spero Therapeutics, Inc. will post -0.58 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SPRO. Alphabet Inc. bought a new stake in shares of Spero Therapeutics in the 2nd quarter valued at approximately $1,967,000. BlackRock Inc. purchased a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $1,314,000. GSA Capital Partners LLP bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at approximately $632,000. Intrepid Family Office LLC increased its position in shares of Spero Therapeutics by 50.0% during the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock valued at $384,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in Spero Therapeutics during the 2nd quarter valued at $55,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company develops therapies for serious bacterial infections and certain rare diseases, with a focus on addressing conditions for which existing treatment options are limited or inadequate.

Spero’s lead program is tebipenem pivoxil hydrobromide, an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections. The company’s pipeline has also included SPR720, an investigational oral therapy for nontuberculous mycobacterial pulmonary disease, and SPR206, an investigational intravenous antibiotic intended for use against serious hospital infections caused by drug-resistant bacteria.

Founded in 2013, Spero has advanced its programs through collaborations and development partnerships, including a former agreement with GlaxoSmithKline.